home / stock / abcl / abcl articles
John Montalbano, Director at AbCellera Biologics (NASDAQ:ABCL), reported a large insider buy on November 8, according to a new SEC filing. What Ha...
Michael Hayden, Board Member at AbCellera Biologics (NASDAQ:ABCL), reported a large insider buy on September 26, according to a new SEC filing. Wh...
Benchmark analyst Robert Wasserman reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ: ABCL), lowering the price targe...
News, Short Squeeze, Breakout and More Instantly...
AbCellera Biologics Inc. Company Name:
ABCL Stock Symbol:
NASDAQ Market:
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, April 16, 2024, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will...
AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience. “Delivering biologics across the blood brain ba...
AbCellera (Nasdaq: ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center. With its T-...